

Resource Summary Report

Generated by [RRID](#) on Aug 6, 2026

CD159a (NKG2A) Antibody, anti-human, PE, REAfinity™

RRID:AB_2726171

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-566, RRID:AB_2726171

Antibody Information

URL: http://antibodyregistry.org/AB_2726171

Proper Citation: Miltenyi Biotec Cat# 130-113-566, RRID:AB_2726171

Target Antigen: CD159a (NKG2A)

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-098-814. (RRID:AB_2655384).

Antibody Name: CD159a (NKG2A) Antibody, anti-human, PE, REAfinity™

Description: This monoclonal targets CD159a (NKG2A)

Target Organism: human

Clone ID: clone REA110

Antibody ID: AB_2726171

Vendor: Miltenyi Biotec

Catalog Number: 130-113-566

Record Creation Time: 20250819T220004+0000

Record Last Update: 20250820T004720+0000

Ratings and Alerts

No rating or validation information has been found for CD159a (NKG2A) Antibody, anti-human, PE, REAfinity™.

No alerts have been found for CD159a (NKG2A) Antibody, anti-human, PE, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Choi SJ, et al. (2023) KIR+CD8+ and NKG2A+CD8+ T cells are distinct innate-like populations in humans. Cell reports, 42(3), 112236.

Krämer B, et al. (2021) Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity, 54(11), 2650.